Immufalk

Azathioprine, the active ingredient in Immufalk, is an antimetabolite immunosuppressant presented as an oral tablet for oral use. It is used to prevent organ transplant rejection and to manage autoimmune and inflammatory bowel diseases in adult patients.

GNH USA supplies Immufalk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Azathioprine is employed in several immune‑mediated conditions to reduce pathological immune activity.

Organ transplant rejection: helps prevent graft rejection by suppressing the host immune response. Rheumatoid arthritis: reduces disease activity and joint inflammation in adult patients. Inflammatory bowel disease (Crohn's disease, ulcerative colitis): maintains remission and decreases intestinal inflammation.

Azathioprine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Loss of appetite - Mild leukopenia or lymphopenia - Skin rash or pruritus - Elevated liver enzymes - Fatigue or headache

Serious or Rare Side Effects: - Severe bone‑marrow suppression (pancytopenia) - Hepatotoxicity or cholestatic liver injury - Pancreatitis - Opportunistic infections - Increased risk of malignancies (e.g., lymphoma) - Severe hypersensitivity reactions

When using azathioprine, careful monitoring and patient education are essential.

Monitor blood counts regularly: detect early bone‑marrow suppression. Assess liver function periodically: identify hepatotoxicity. Screen for infections before initiation: avoid exacerbating latent infections. Avoid in patients with known hypersensitivity to azathioprine or its metabolites. Use caution in renal or hepatic impairment: dose adjustments may be required. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Azathioprine interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Allopurinol or febuxostat: can cause profound myelosuppression. - Warfarin: azathioprine may enhance anticoagulant effect, increasing bleeding risk. - Live vaccines: immunosuppression may lead to uncontrolled infection. - Ribavirin: combined use raises risk of severe hematologic toxicity. - Methotrexate: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may increase risk of renal dysfunction. - NSAIDs: can worsen renal impairment and affect platelet function. - Trimethoprim‑sulfamethoxazole: may enhance myelosuppression. - Azole antifungals: can increase azathioprine plasma levels. - Oral contraceptives: azathioprine may reduce hormonal efficacy.